WHO ICTRP trial
Noribogaine Therapy for Relief of Opioid withdrawal, Phase 1B
ACTRN12613001064796 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Not Recruiting
Key facts
| Trial ID | ACTRN12613001064796 |
|---|---|
| Public title | Noribogaine Therapy for Relief of Opioid withdrawal, Phase 1B |
| Scientific title | A Phase 1B, Single Center, Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Noribogaine in Opioid Dependent Participants Seeking to Discontinue Methadone Opioid Substitution Treatment (OST) |
| Primary sponsor | DemeRx Inc |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 1 |
| Countries | New Zealand |
| Conditions | Symptoms of opioid withdrawal; Symptoms of opioid withdrawal;Mental Health - Addiction |
| Interventions | Administration of a single oral dose of noribogaine. It is planned that the first dose cohort will receive 60mg, the second cohort 120mg and the third cohort 180mg. Noribogaine will be administered under supervision at the study site. |
| Registration date | Sep 24, 2013 |
| Target size | 27 |
| Secondary IDs | ZPS-513 (Protocol ID) |
| Registry page | anzctr.org.au |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: